Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
14.5 to 22 months
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and 85 years inclusive
Meets criteria for probable Alzheimer's of the National Institute of Neurologic and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association
Mini-mental state examination (MMSE)
In reasonable and stable health state for Alzheimer's patients of this age and stage of disease as assessed by a comprehensive clinical assessment
Magnetic resonance imaging consistent with Alzheimer's disease, not indicating any other cause for dementia symptoms than Alzheimer's disease
Rosen Modified Hachinski Ischemic score
If on symptomatic treatment for Alzheimer's disease (acetylcholinesterase inhibitors or/and memantine), must be stable in the last 30 days before screening
You may not be if
Clinically significant neurological disease other than Alzheimer's disease
Had a major psychiatric disorder
Had a history of stroke, seizures, brain neoplasms, brain surgery, or any cerebrovascular disorder (including transient ischemic attack)
History or presence of severe, uncontrolled and/or unstable angiopathy or vasculitis.
History or presence of clinically relevant cardiac disease.
Currently taking anticonvulsants, anti-Parkinsonians, antipsychotics, anticoagulants or narcotic drugs, recent immunosuppressive or cancer chemotherapy drugs, or cognitive enhancers. Concomitant therapies that are allowed if given at a stable dose for at least 30 days before screening are: acetylcholinesterase inhibitors and/or memantine; antidepressants of the class of selective serotonin reuptake inhibitors (no tricyclics); acetyl salicylic acid (ASA) at a dose ≤ 160 mg/day;
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
